FDA Initiates Class II Recall for Sulfamethoxazole and Trimethoprim Due to Packaging Contamination
Cardinal Health 107, LLC faces a Class II FDA recall for Sulfamethoxazole and Trimethoprim, USP, 800 mg/160 mg. The recall, initiated by The Harvard Drug Group LLC, stems from microorganism detection on auxiliary polyester coil packaging, not the drug itself. This nationwide U.S. distribution disruption highlights critical packaging supplier oversight and quality control needs, impacting procurement and supply chain continuity for this essential antibiotic.
FDA Class II Recall: Sulfamethoxazole and Trimethoprim Packaging Contamination
The U.S. Food and Drug Administration (FDA) has initiated a Class II recall, D-0625-2025, for Sulfamethoxazole and Trimethoprim, USP, 800 mg/160 mg, Double Strength tablets. This critical regulatory action, initiated on September 2, 2025, by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories, directly impacts the availability of this widely prescribed antibiotic across the United States. The recall specifically targets product distributed by Cardinal Health, Dublin, OH 43017, under NDC 55154-7895-0 (Outer Bag) and NDC 0904-2725-61 (Inner blisters), with lot numbers N02309A and N02309B for the bags, and N02309 for the inner blisters, all expiring March 31, 2027. For procurement directors and supply chain VPs, this means an immediate need to quarantine and return affected inventory to prevent further distribution. The core issue, identified as the presence of a micro-organism on a specific lot of auxiliary polyester coil used in product packaging, supplied by Amneal Pharmaceuticals LLC, underscores the vulnerability of the supply chain beyond active pharmaceutical ingredients (APIs). While no micro-organism was detected on the tablets themselves, the Class II classification indicates that the use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates a swift and decisive response to mitigate potential patient risk and maintain regulatory compliance.
Operational Impact and Distribution Challenges for Cardinal Health 107, LLC
The recall places significant operational burdens on Cardinal Health 107, LLC, identified as a manufacturer of Sulfamethoxazole and Trimethoprim, and a key distributor. The company's facility in La Vergne, TN, United States, is central to its manufacturing and distribution network. Given the nationwide distribution pattern of the affected product, recall logistics are complex, requiring extensive coordination across warehouses, pharmacies, and healthcare providers throughout the USA. For business development executives and supply chain VPs, this event highlights the intricate challenges of managing product integrity across a broad distribution network. The recall of a high-volume generic drug like Sulfamethoxazole and Trimethoprim, a combination antibiotic used to treat various bacterial infections, can lead to substantial financial implications, including costs associated with product retrieval, destruction, and potential loss of sales. Furthermore, the incident necessitates a thorough internal review of quality assurance protocols for packaging materials and supplier management, particularly concerning components sourced from third parties like Amneal Pharmaceuticals LLC. This disruption could strain relationships with downstream customers and impact Cardinal Health's reputation for supply reliability, demanding transparent communication and robust corrective actions.
Supply Chain Disruption: Sourcing Sulfamethoxazole and Trimethoprim Post-Recall
The nationwide recall of Sulfamethoxazole and Trimethoprim, USP, 800 mg/160 mg, presents an immediate supply chain challenge for healthcare systems and pharmacies reliant on this essential generic antibiotic. Procurement directors must urgently assess their inventory levels and identify alternative sourcing strategies to ensure continuity of patient care. The absence of specific alternative suppliers in the available intelligence underscores the critical need for organizations to maintain diversified supplier portfolios for key generic medications. This event serves as a stark reminder for supply chain VPs about the fragility of single-source or concentrated supply chains, even for packaging components. While the product itself was not contaminated, the packaging issue has rendered the entire lot unusable, creating a functional shortage. Businesses must now evaluate their current contracts and relationships with other manufacturers of Sulfamethoxazole and Trimethoprim to secure immediate and long-term supply. This includes assessing lead times, pricing, and the regulatory standing of potential new suppliers. Proactive engagement with regulatory affairs teams is crucial to expedite the qualification of any new sources, minimizing disruption to patient access and maintaining operational stability.
Strategic Procurement: Enhancing Packaging Component Supplier Qualification
This recall underscores a critical lesson for procurement directors: the quality and regulatory compliance of all components, including packaging materials, are as vital as the active pharmaceutical ingredients themselves. The detection of a micro-organism on auxiliary polyester coil from Amneal Pharmaceuticals LLC highlights a potential gap in supplier qualification and incoming material inspection processes. For regulatory affairs heads and procurement teams, this necessitates a re-evaluation of current supplier audit programs. It is imperative to extend rigorous quality oversight beyond API manufacturers to all critical material suppliers, including those providing packaging components. This involves implementing robust vendor qualification processes, conducting regular audits that include sterility and foreign substance detection protocols, and establishing clear quality agreements with all suppliers. Furthermore, internal quality control departments must strengthen incoming material inspection procedures to proactively identify and mitigate risks associated with packaging components. Investing in advanced analytical testing for packaging materials can prevent costly recalls, protect patient safety, and safeguard brand reputation, ultimately reducing long-term business risk and ensuring uninterrupted supply of critical medications like Sulfamethoxazole and Trimethoprim.
Broader Regulatory Scrutiny: Packaging Integrity and Sterility Assurance
This Class II recall, while specific to packaging contamination, aligns with a broader trend of increased FDA scrutiny on product integrity and sterility assurance across the pharmaceutical industry. The incident involving Sulfamethoxazole and Trimethoprim packaging echoes concerns seen in other recent regulatory actions. For instance, the FDA's Class II recall of Essential Wellness Pharma's Progesterone Injection in June 2026 due to sterility assurance failures, though concerning the drug product itself, highlights the agency's unwavering focus on preventing microbial contamination at any point in the manufacturing and supply chain. Regulatory affairs heads must recognize that the FDA's enforcement priorities encompass all aspects of Good Manufacturing Practices (GMPs), including the quality control of non-drug components. This incident signals that packaging material suppliers, such as Amneal Pharmaceuticals LLC in this case, will likely face heightened scrutiny. Companies must proactively review their entire quality management system, from raw material sourcing to finished product distribution, to identify and address potential vulnerabilities. A robust quality culture that extends to all third-party suppliers is no longer merely a best practice but a regulatory imperative, crucial for maintaining market access and avoiding costly disruptions for essential medicines like Sulfamethoxazole and Trimethoprim.